Lv1
58 积分 2021-12-04 加入
Neoadjuvant savolitinib targeted therapy for stage IIIB-N3 lung adenocarcinoma harboring mesenchymal–epithelial transition exon 14 skipping mutation: a case report and literature review
8小时前
已完结
Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials
5天前
已完结
Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer
17天前
已完结
Microwave ablation combined with EGFR-TKIs versus only EGFR-TKIs in advanced NSCLC patients with EGFR-sensitive mutations
1个月前
已完结
First-Line Integration of Local Ablative Therapy With EGFR Tyrosine Kinase Inhibitors in Advanced EGFR+ NSCLC: A Systematic Review and Meta-Analysis
1个月前
已完结
First-line integration of Local Ablative Therapy (LAT) with EGFR Tyrosine Kinase Inhibitors (TKIs) in advanced EGFR+ NSCLC: A Systematic Review and Meta-Analysis
1个月前
已完结
Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC
1个月前
已完结
Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study
1个月前
已完结
First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 Study
1个月前
已完结
Current indications for surgery in patients with lung cancer after neoadjuvant targeted therapy: a systematic review
1个月前
已完结
皖公网安备34019202002308
